This is an outdated version published on 2023-09-14. Read the most recent version.

Systemic immunomodulatory therapy in the management of atopic dermatitis: the value of Tralokinumab


  • Sara Muñoz Ordóñez FUNINDERMA
  • Jessika Alexandra Layos Universidad autónoma de Bucaramanga
  • Maria Paula Garcia Lozano Universidad del Rosario
  • Yelson Alejandro Picón Jaimes Universidad Ramón Llul



Atopic Dermatitis, Tralokinumab, Immunomodulation, Interleukin-13, Immunosuppression Therapy




Download data is not yet available.


Kelly KA, Perche PO, Feldman SR. Therapeutic Potential of Tralokinumab in the Treatment of Atopic Dermatitis: A Review on the Emerging Clinical Data. Clin Cosmet Investig Dermatol. 2022; 15:1037-1043. DOI: 10.2147/CCID.S267217

Singh R, Taylor A, Shah MA, Strowd LC, Feldman SR. Review of Tralokinumab in the Treatment of Atopic Dermatitis. Ann Pharmacother. 2023; 57(3):333-340. DOI: 10.1177/10600280221105686

Drucker AM, Morra DE, Prieto-Merino D, Ellis AG, Yiu ZZN, Rochwerg B, et al. Systemic Immunomodulatory Treatments for Atopic Dermatitis: Update of a Living Systematic Review and Network Meta-analysis. JAMA Dermatol. 2022; 158(5):523-532. DOI: 10.1001/jamadermatol.2022.0455

Institute of Medicine (US) Committee on the US Commitment to Global Health. The US Commitment to Global Health: Recommendations for the Public and Private Sectors. Washington (DC): National Academies Press (US); 2009. Summary. Disponible en:

Silverberg JI, Toth D, Bieber T, Alexis AF, Elewski BE, Pink AE, et al. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol. 2021; 184(3):450-463. DOI: 10.1111/bjd.19573

Gutermuth J, Pink AE, Worm M, Soldbro L, Bjerregård Øland C, Weidinger S. Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo-controlled, randomized, phase III clinical trial (ECZTRA 7). Br J Dermatol. 2022; 186(3):440-452. DOI: 10.1111/bjd.20832

Soehoel A, Larsen MS, Timmermann S. Population Pharmacokinetics of Tralokinumab in Adult Subjects With Moderate to Severe Atopic Dermatitis. Clin Pharmacol Drug Dev. 2022; 11(8):910-921. DOI: 10.1002/cpdd.1113

Lai B, Phan K, Lewis N, Shumack S. A rare case of vernal keratoconjunctivitis in a patient with atopic dermatitis treated with tralokinumab. J Eur Acad Dermatol Venereol. 2022; 36(5):e343-e345. DOI: 10.1111/jdv.17824

Wang B, Goodman J, Roskos LK. Mechanistic modeling of a human IgG4 monoclonal antibody (tralokinumab) Fab-arm exchange with endogenous IgG4 in healthy volunteers. CPT Pharmacometrics Syst Pharmacol. 2022; 11(4):438-446. DOI: 10.1002/psp4.12738

Lozada-Martinez ID, Suarez-Causado A, Solana-Tinoco JB. Ethnicity, genetic variants, risk factors and cholelithiasis: The need for eco-epidemiological studies and genomic analysis in Latin American surgery. Int J Surg. 2022; 99:106589. DOI: 10.1016/j.ijsu.2022.106589

Adikusuma W, Irham LM, Chou WH, Wong HS, Mugiyanto E, Ting J, et al. Drug Repurposing for Atopic Dermatitis by Integration of Gene Networking and Genomic Information. Front Immunol. 2021; 12:724277. DOI: 10.3389/fimmu.2021.724277

Pérez-Fontalvo NM, De Arco-Aragón MA, Jimenez-García JDC, Lozada-Martinez ID. Molecular and computational research in low- and middle-income countries: Development is close at hand. J Taibah Univ Med Sci. 2021; 16(6):948-949. DOI: 10.1016/j.jtumed.2021.06.010

How to Cite

Muñoz Ordóñez , S., Layos , J. A. ., Garcia Lozano, M. P. ., & Picón Jaimes, Y. A. (2023). Systemic immunomodulatory therapy in the management of atopic dermatitis: the value of Tralokinumab. Revista De La Facultad De Medicina Humana, 23(3).